Hormone replacement therapy.
About this work
A discussion between John Studd from King's College Hospital Medical School and Mr. Geoffrey Chamberlain. The following summary accompanies the cassette: "Following ovarian failure there is a 13-fold increase in plasma FSH and a 3-fold increase in luteinizing hormone together with a fall in oestrone and oestradiol to 20% of their normal follicular phase values. Oestrogen therapy will remove most of the symptoms of the climacteric but there is no doubt that unopposed oestrogens carry a risk of hyperplasmia and possibly endometrial carcinoma. Hyperplasia can be prevented by giving 10 days of a progestogen with the cyclical oestrogen therapy and this should be the recommended regimen of therapy. If cystic glandular hyperplasia does occur with unopposed oestrogens it can invariably be corrected with two 21 day courses of a progestogen. Scanning electron microscopy is being used to characterise the cell surface morphology in normal hyperplastic malignant endometrial cells."